The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults

Early Phase 1

Not yet recruiting

• Conditions: Acute Leukemia
• Interventions: Drug: Bevacizumab

• Registration Number: NCT06876701
• Lead Sponsor: Ruijin Hospital

Brief Summary

Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-03
• Study First Submitted: 2025-03-10
• Study First Submitted QC: 2025-03-10
• Last Update Submitted: 2025-03-10
• Study First Posted: 2025-03-14
• Last Update Posted: 2025-03-14
• Study Start: 2025-04-01
• Primary Completion: 2027-04-01
• Study Completion: 2027-04-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF);
2. Age: 18-75 years old (including boundary values of 18 and 75);
3. Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity

Exclusion Criteria

The subject's previous history of anti-tumor treatment meets one of the following conditions:

1. Individuals who have previously received bevacizumab
2. Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening;
3. Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Experimental group	Bevacizumab	-

Primary Outcome Measures

Name	Time	Method
Negative conversion rate of evaluable residual lesions (MRD)	1 year

Trial Locations

Locations (1)

Shanghai Zhaxin integrated hospital of traditional Chinese and Western Medicine; 🇨🇳 Shanghai, China